| 2026-08-12 | Theme Refresh Synthesis | The GLP-1 theme remains robust, driven by strong demand and innovation. Hims & Hers is poised for rapid entry into the peptide wellness market, with 6 of 7 peptides passing PCAC review. Halozyme's Hypercon and expanded ENHANZE collaborations support advanced peptide delivery. Stevanato sees GLP-1s as 22-23% of revenue with double-digit growth, bolstered by Alina pen approval. Camurus' once-monthly semaglutide depot advances, underscoring long-acting peptide delivery's importance. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-13 | Theme Refresh Synthesis | The GLP-1 theme remains robust. Hims & Hers' 6 of 7 peptides passing PCAC review signals broader market entry. Halozyme's Hypercon and ENHANZE expansion into ADCs/nucleic acids, alongside Camurus' once-monthly semaglutide depot, highlight advanced peptide delivery innovation. Stevanato's 22-23% GLP-1 revenue and Alina pen approval, coupled with Lonza's CDMO role and PeptiDream's discovery platform, reinforce strong demand and technological advancements across the peptide ecosystem. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-14 | Theme Refresh Synthesis | The GLP-1 theme remains robust, driven by continued innovation and market expansion. Hims & Hers' 6 of 7 peptides passing PCAC review signals broader market entry for compounded therapies. Halozyme's ENHANZE/Hypercon platforms are diversifying peptide delivery into ADCs and nucleic acids. Stevanato Group reports strong GLP-1 revenue (22-23%) and Alina pen approval, while Camurus advances its once-monthly semaglutide depot. Lonza and PeptiDream further strengthen the peptide ecosystem, underscoring sustained demand and technological advancements. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-15 | Theme Refresh Synthesis | The GLP-1 theme remains robust. Hims & Hers' 6 of 7 peptides passing PCAC review signals broader market entry for compounded therapies, despite profitability pressures. Halozyme's ENHANZE/Hypercon diversify peptide delivery into ADCs/nucleic acids. Stevanato Group reports strong GLP-1 revenue (22-23%) and Alina pen approval. Camurus advances its once-monthly semaglutide depot. Overall, sustained demand and technological advancements bolster the peptide ecosystem. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-16 | Theme Refresh Synthesis | The GLP-1 theme remains robust. Hims & Hers' 6 of 7 peptides passing PCAC review signals broader market entry for compounded therapies, despite profitability pressures. Halozyme's ENHANZE/Hypercon diversify peptide delivery into ADCs/nucleic acids. Stevanato Group reports strong GLP-1 revenue (22-23%) and Alina pen approval. Camurus advances its once-monthly semaglutide depot. Overall, sustained demand and technological advancements bolster the peptide ecosystem. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-18 | Theme Refresh Synthesis | The GLP-1 theme remains bullish, reinforced by Hims & Hers' 6 of 7 peptides passing PCAC review, signaling broader compounded therapy market entry. Halozyme's new ENHANZE deals for ADCs and nucleic acids, plus Hypercon's progress, highlight peptide application diversification. Stevanato's Alina pen approval and capacity expansions underscore delivery innovation. While demand is robust, Hims & Hers' negative free cash flow and PeptiDream's rising R&D costs reflect ongoing profitability pressures. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-19 | Theme Refresh Synthesis | The GLP-1 theme remains bullish. Hims & Hers' 6 of 7 peptides passing PCAC review signals significant compounded therapy market expansion. Halozyme's record royalty growth and new ENHANZE/Hypercon deals into ADCs and nucleic acids highlight peptide technology diversification. Stevanato Group's strong GLP-1 revenue and Alina pen approvals underscore delivery system demand. Camurus' once-monthly semaglutide depot advances long-acting innovation, while profitability pressures (Hims, PeptiDream) persist. | | Bullish | HIMS, HALO, STVN, CAMX.ST, 4587.T, LONN.SW |
| 2026-08-20 | Theme Refresh Synthesis | The GLP-1 theme remains bullish, driven by robust demand and expanding peptide applications. Hims & Hers' PCAC success signals growth in compounded therapies, despite profitability pressures. Halozyme's record royalties and new ENHANZE/Hypercon deals into ADCs/nucleic acids highlight diversification. Stevanato Group sees strong GLP-1 revenue and delivery system demand. Lonza and Camurus advance manufacturing and long-acting formulations, reinforcing the theme's strong innovation and market expansion. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-21 | Theme Refresh Synthesis | The GLP-1 theme remains bullish. Hims & Hers' PCAC success for compounded peptides signals market expansion, despite profitability pressures from scaling. Halozyme's record royalties and new ENHANZE/Hypercon deals into ADCs/nucleic acids highlight peptide technology diversification. Stevanato Group sees strong GLP-1 revenue and delivery system demand. Camurus advances long-acting semaglutide, while Lonza supports manufacturing, reinforcing robust innovation and market growth. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-22 | Theme Refresh Synthesis | The GLP-1 theme remains bullish. Hims & Hers' PCAC success for compounded peptides signals market expansion. Halozyme's record royalties and new ENHANZE/Hypercon deals into ADCs/nucleic acids highlight peptide technology diversification. Stevanato Group sees strong GLP-1 revenue and delivery system demand, while Camurus advances long-acting semaglutide. Lonza supports manufacturing, reinforcing robust innovation and market growth, despite profitability pressures from Hims and PeptiDream's investments. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-23 | Theme Refresh Synthesis | The GLP-1 theme remains bullish. Hims & Hers' PCAC success for compounded peptides and US-based API manufacturing readiness signals market expansion. Halozyme's record royalties and ENHANZE/Hypercon diversification into ADCs/nucleic acids highlight expanding peptide applications. Stevanato Group's strong GLP-1 revenue and Alina pen approvals underscore delivery system demand. Camurus advances long-acting semaglutide, while Lonza supports manufacturing, despite profitability pressures from Hims and PeptiDream's investments. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-24 | Theme Refresh Synthesis | The GLP-1 theme remains bullish. Hims & Hers' PCAC success for 6 of 7 peptides signals significant compounded therapy market expansion, despite profitability pressures from scaling. Halozyme's record royalties and ENHANZE/Hypercon diversification into ADCs/nucleic acids highlight expanding peptide applications. Stevanato Group's strong GLP-1 revenue and Alina pen approvals underscore delivery system demand. Camurus advances long-acting semaglutide, while Lonza supports manufacturing, reinforcing robust innovation and market growth. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-25 | Theme Refresh Synthesis | The GLP-1 theme remains bullish. Hims & Hers' PCAC success for 6 of 7 peptides signals significant compounded therapy market expansion, despite profitability pressures. Halozyme's ENHANZE/Hypercon diversification into ADCs/nucleic acids highlights expanding peptide applications. Stevanato Group's strong GLP-1 revenue and Alina pen approvals underscore delivery system demand. Camurus advances long-acting semaglutide, while Lonza supports manufacturing, reinforcing robust innovation and market growth. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-26 | Theme Refresh Synthesis | The GLP-1 theme remains bullish, driven by expanding applications and robust demand. Hims & Hers' PCAC success for 6 of 7 peptides signals significant compounded therapy market growth, despite profitability pressures. Halozyme's record royalties and ENHANZE/Hypercon diversification into ADCs/nucleic acids highlight broader peptide technology advancements. Stevanato's strong GLP-1 revenue and Alina pen approvals underscore delivery system demand. Camurus advances long-acting semaglutide, while Lonza supports manufacturing, reinforcing innovation. PeptiDream faces revenue volatility. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-08-27 | Theme Refresh Synthesis | The GLP-1 theme remains bullish, driven by robust demand and expanding peptide applications. Hims & Hers' PCAC success for 6 of 7 peptides signals significant compounded therapy market growth, despite profitability pressures. Halozyme's record royalties and ENHANZE/Hypercon diversification into ADCs/nucleic acids highlight broader peptide technology advancements. Stevanato's strong GLP-1 revenue and Alina pen approvals underscore delivery system demand. Camurus advances long-acting semaglutide, while Lonza supports manufacturing, reinforcing innovation. PeptiDream faces revenue volatility. | | Bullish | HIMS, HALO, STVN, CAMX.ST, LONN.SW, 4587.T |
| 2026-11-01 | Theme Refresh Synthesis | The GLP-1 theme remains robust, driven by accelerating demand for peptide APIs and delivery systems. Companies like West and Aptar report strong growth in GLP-1 related components, while Stevanato and Ypsomed expand capacity for devices and fill-finish. Innovation in long-acting formulations (Camurus) and automation (ATS) reinforces the theme's bullish outlook, supported by regulatory tailwinds. | | Bullish | WST, ATR, BDX, ATS.TO, STVN, CAMX.ST, YPSN.SW, NEULANDLAB.NS, SAILIFE.NS |
| 2026-11-11 | Theme Refresh Synthesis | This theme refresh synthesis confirms the GLP-1 theme's robust, bullish outlook, fueled by accelerating demand for peptide APIs and delivery systems. Key players like West and Aptar report strong growth in GLP-1 components, while Stevanato and Ypsomed expand device and fill-finish capacity. Innovation in long-acting formulations (Camurus) and automation (ATS) further reinforces this positive trend, supported by regulatory tailwinds. | | Bullish | WST, ATR, BDX, ATS.TO, STVN, CAMX.ST, YPSN.SW, NEULANDLAB.NS, SAILIFE.NS |
| 2026-11-12 | Theme Refresh Synthesis | The GLP-1 theme remains bullish, driven by strong demand for delivery systems and components, with West reporting GLP-1 organic growth accelerating into the 30s. While Stevanato faces a temporary, customer-specific GLP-1 headwind for 2027, non-GLP biologics are robust. Innovation in long-acting formulations (Camurus) and expanding manufacturing capacity (Ypsomed, Asymchem) reinforce the theme's long-term positive outlook. | | Bullish | WST, STVN, ATR, BDX, CAMX.ST, YPSN.SW, 6821.HK |
| 2026-11-13 | Theme Refresh Synthesis | The GLP-1 theme remains bullish, driven by West's accelerating GLP-1 component growth into the 30s and strong injectable demand for Aptar. While Stevanato faces a temporary 2027 GLP-1 customer-specific headwind, robust non-GLP biologics growth provides resilience. Capacity expansions by Ypsomed and Asymchem, alongside Camurus' long-acting semaglutide progress, reinforce sustained demand for manufacturing, fill-finish, and delivery solutions. | | Bullish | WST, STVN, ATR, BDX, CAMX.ST, YPSN.SW, 6821.HK, ATS.TO |
| 2026-11-14 | Theme Refresh Synthesis | The GLP-1 theme remains robust. West's GLP-1 component growth accelerated into the 30s, and Aptar saw strong injectable demand. While Stevanato faces a temporary 2027 GLP-1 customer-specific headwind, strong non-GLP biologics growth provides resilience. Capacity expansions by Ypsomed and Asymchem, alongside Camurus' long-acting semaglutide progress, reinforce sustained demand for manufacturing, fill-finish, and delivery solutions. | | Bullish | WST, STVN, ATR, BDX, CAMX.ST, YPSN.SW, 6821.HK, ATS.TO |
| 2026-11-15 | Theme Refresh Synthesis | The GLP-1 theme remains robust, driven by West's accelerating GLP-1 component growth into the 30s and strong injectable demand for Aptar. Capacity expansions by Asymchem and Ypsomed, alongside Camurus' long-acting semaglutide progress, reinforce sustained demand for manufacturing, fill-finish, and delivery solutions. Stevanato's temporary GLP-1 headwind is offset by strong non-GLP biologics, highlighting theme resilience. | | Bullish | WST, ATR, STVN, YPSN.SW, 6821.HK, CAMX.ST, BDX, ATS.TO |
| 2026-11-17 | Theme Refresh Synthesis | The GLP-1 theme remains robust and bullish, driven by West's accelerating GLP-1 component growth and Aptar's strong injectable demand. Ypsomed expands capacity and client base for delivery systems. Camurus advances long-acting formulations. Stevanato's temporary GLP-1 headwind is offset by strong non-GLP biologics, showcasing theme resilience. Automation (ATS) and broader biologic delivery (BDX) further reinforce the positive outlook for manufacturing, fill-finish, and drug delivery solutions. | | Bullish | WST, ATR, YPSN.SW, CAMX.ST, STVN, ATS.TO, BDX |